CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CRISPR Therapeutics has announced its participation in two virtual investor conferences in June 2020. The Jefferies Global Healthcare Conference will take place on June 2, 2020, at 1:30 p.m. ET. The company will also join the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020, at 9:40 a.m. ET. Investors can access live webcasts of both events on the company's website, with a replay available for 14 days post-presentation. CRISPR Therapeutics focuses on developing gene-based medicines for serious diseases utilizing its proprietary CRISPR/Cas9 technology.

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:

Jefferies Global Healthcare Conference
Date: Tuesday, June 2, 2020
Fireside chat: 1:30 p.m. ET

Goldman Sachs 41st Annual Global Healthcare Conference
Date: Tuesday, June 9, 2020
Fireside chat: 9:40 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Investor Contact:
Susan Kim
+1 617-307-7503
susan.kim@crisprtx.com 

Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1 617-337-4167
reides@wcgworld.com 

FAQ

What are the dates for CRSP's investor conferences in June 2020?

CRISPR Therapeutics is participating in the Jefferies Global Healthcare Conference on June 2, 2020, and the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020.

What time will CRSP's presentations occur during the investor conferences?

The Jefferies Global Healthcare Conference fireside chat is at 1:30 p.m. ET on June 2, 2020. The Goldman Sachs conference fireside chat is at 9:40 a.m. ET on June 9, 2020.

Where can I watch the CRSP investor conference presentations?

Investors can access the live webcasts of CRISPR Therapeutics' presentations on the 'Events & Presentations' page of their website.

How long will the replay of CRSP's conference presentations be available?

The replay of CRISPR Therapeutics' webcast will be available for 14 days following each presentation.

What is CRSP's focus in biopharmaceutical development?

CRISPR Therapeutics focuses on creating gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology.